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Abstract
Background: Proteomics is expected to play a key role in cancer biomarker discovery. Although it has become feasible to
rapidly analyze proteins from crude cell extracts using mass spectrometry, complex sample composition hampers this type
of measurement. Therefore, for effective proteome analysis, it becomes critical to enrich samples for the analytes of interest.
Despite that one-third of the proteins in eukaryotic cells are thought to be phosphorylated at some point in their life cycle,
only a low percentage of intracellular proteins is phosphorylated at a given time.
Methodology/Principal Findings: In this work, we have applied chromatographic phosphopeptide enrichment techniques
to reduce the complexity of human clinical samples. A novel method for high-throughput peptide profiling of human tumor
samples, using Parallel IMAC and MALDI-TOF MS, is described. We have applied this methodology to analyze human normal
and cancer lung samples in the search for new biomarkers. Using a highly reproducible spectral processing algorithm to
produce peptide mass profiles with minimal variability across the samples, lineal discriminant-based and decision tree–
based classification models were generated. These models can distinguish normal from tumor samples, as well as
differentiate the various non–small cell lung cancer histological subtypes.
Conclusions/Significance: A novel, optimized sample preparation method and a careful data acquisition strategy is
described for high-throughput peptide profiling of small amounts of human normal lung and lung cancer samples. We
show that the appropriate combination of peptide expression values is able to discriminate normal lung from non-small cell
lung cancer samples and among different histological subtypes. Our study does emphasize the great potential of
proteomics in the molecular characterization of cancer.
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Introduction
In Western countries, lung cancer represents the leading cause
of cancer-related death [1]. The 5-year overall survival rate is 15%
and has not improved over many decades. This is mainly because
approximately two-thirds of lung cancers are discovered at
advanced stages. Furthermore, even among early-stage patients
who are treated primarily by surgery with curative intent, 30–55%
will develop and die of metastasis recurrence [2].
Today, lung cancer is classified according to histological
criteria. The four main subtypes are: small cell lung cancer
(SCLC), squamous cell carcinoma (SC), adenocarcinoma (AC),
and large cell carcinoma (LC). Clinically, the last three are
considered as non-small cell lung cancer (NSCLC), which
accounts for about the 85% of all lung cancers [3]. Precise
diagnosis and classification of cancers are critical for the selection
of appropriate therapies. The advent of effective targeted
therapies for lung cancer, such as the epidermal growth factor
receptor inhibitors erlotinib and gefitinib, and the prospect of
developing additional targeted therapies, has emphasized the
importance of accurate diagnosis [4].
Proteomics is expected to play a key role in cancer biomarker
discovery. Although it has become feasible to rapidly analyze
proteins from crude cell extracts using mass spectrometry, sample
complexity complicates these studies [5,6]. Therefore, for effective
proteome analysis it is essential to enrich samples for the analytes
of interest [7]. Despite the fact that one-third of the proteins in
eukaryotic cells are thought to be phosphorylated at some point in
their life cycle, only a low percentage of the intracellular proteins is
phosphorylated at any given time [8,9]. Thus, a purification or
enrichment step that isolates phosphorylated species would reduce
complexity and increase sensitivity [10].
MALDI profiling is one of the most promising techniques to
reduce the gap between high-throughput proteomics and clinic
[7,11]. MALDI MS can be used as a high-throughput method with
outstanding sensitivity [6], enabling studies compromising large
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diagnosis of many diseases [12]. This capacity has been exemplified
byMALDIproteinprofilingontumorsamples,which permittedthe
identification of markers that could be correlated with histological
assessment and patientoutcomesthroughstatisticalanalysis[13,14].
In this work, we applied phosphopeptide enrichment techniques to
small human clinical samples based on Immobilized Metal Affinity
Chromatography (IMAC) to reduce sample complexity. To detect
new biomarkers, we have defined a data analysis workflow applying
lineal discriminant-based and decision tree-based classification
methods to analyze peptide profiles from human normal and




the sense that their tumour samples could be used for investigational
purposes. Institutional approval from our ethical committee was
obtained for the conduct of the study (Comite ´E ´tico de Investigacio ´n
Clı ´nica, Hospital Universitario La Paz). Data were analyzed
anonymously. Patients provided written consent so that their
samples and clinical data could be used for investigational purposes.
Sample selection
Frozen samples from patients diagnosed with lung cancer: (15
Adenocarcinoma (AC), 15 Squamous cell carcinoma (SC) and 14
large cell carcinoma (LC) samples) and 15 normal lung (NL)
samples were retrieved from the Department of Pathology of
Hospital Universitario La Paz (Madrid, Spain). The histopatho-
logical features of each sample were reviewed by an experienced
lung pathologist to confirm diagnosis and tumor content. Eligible
samples had to include at least 50% of tumor cells.
Total protein extraction, solubilization, and digestion
Samples were cut in a Leica CM3050S cryostat, obtaining 10
sections of 10 microns thickness of each. Tissue was processed with
TRIzol reagent (Invitrogen, Carsbald, CA, USA) following the
manufacturer’s instructions. Pellets were resuspended in guanidine
hydrochloride 6 M and heated 10 minutes at 95uC with agitation.
Subsequently, 950 ml of 50 mM ammonium bicarbonate (pH 7–9)
per sample were added. Protein sample concentration was
measured by MicroBCA Protein Assay Kit (Pierce-Thermo
Scientific, Rockford, IL, USA). Trypsin MS Grade Gold
(Promega, Madison, WI, USA) was added to each sample to a
1:50 relation. Digestion was carried out overnight at 37uC. The
digested sample was divided into two aliquots.
Parallel IMAC (PIMAC)
IMAC-Fe(III) based was performed in one aliquot of digested
protein with PHOS-Select Iron Affinity Gel (Sigma-Aldrich, St.
Louis, MO, USA) following the manufacturer’s instructions.
IMAC-based Ga(III) was performed in the other aliquot of
digested protein with Phosphopeptide Isolation Kit (Pierce-
Thermo Scientific, Rockford, IL, USA) following the manufac-
turer’s instructions. Samples were stored at 220uC until further
analysis.
Phosphopeptide analysis by mass spectrometry
Peptide mixtures were vacuum dried and dissolved in a solution
containing acetonitrile (30%) and TFA (0.1%). After bath-
sonication (3 min), the peptides were 1:1 mixed with either
a-Cyano-4-hydroxycinnamic acid (CHCA) or 2,5-dihydroxyben-
zoic acid (DHB) used as matrices. A volume of 0.5 ml was
deposited on the MALDI plate and was kept at room temperature
until dried. MALDI-MS spectra (two replicates) were measured on
a Bruker Ultraflex TOF/TOF MALDI mass spectrometer
(Bruker-Daltonics, Billerica, MA, USA) [15] in the positive ion
reflector mode. For protein identification, the peptide ions of
interest were subject to MALDI-MS/MS analysis in the TOF/
TOF mode, and the corresponding MS/MS spectra were
transferred through the MS BioTools program (Bruker-Daltonics,
Billerica, MA, USA) as inputs to search the NCBInr database
using MASCOT software (Matrix Science, London, UK) [16].
Differential m/z peaks selection
ClinProTools (CPT) software 2.1 (Bruker-Daltonics, Billerica,
MA, USA) was used to select differential m/z peaks among
samples subtypes (NL, AC, SC and LC). Spectra were processed as
follows:
1) Normalization of all spectra to their Total Ion Count,
2) Recalibration of spectra on each other using the most
prominent m/z peaks,
3) Baseline subtraction and m/z peak detection.
Once standardized and adjusted, CPT selects mass ranges which
were considered as m/z peaks, and calculates peak areas for each
spectrum [17]. Spectra were divided into two sets (Set 1 and Set 2),
which include a different spot measurement per sample. Each set
was divided in four spectra groups depending on the combinations
between MALDI matrix and IMAC metal (Mx-Mt) used to obtain
them (DHB-Fe, DHB-Ga, CHCA-Fe and CHCA-Ga). Each of
these spectra groups were subsequently divided into histological
subgroups (NL, AC, SC and LC) and analyzed separately by CPT.
CPT settings were S/N.3 and Savitzky-Golay smoothing (1 cycle,
m/z range=5) [18]. The combination of these lists gives a
combined Mx-Mt m/z peak list. Then we included all spectra of
one Mx-Mt combination in CPT to measure all m/z peaks in the
correspondent combined Mx-Mt m/z peak list. Peaks with Kruskal-
Wallis p-value.0.1 were discarded. Common m/z peaks between
two sets were selected. Finally, Pearson test between area values of
each m/z peak achieved in Set 1 and Set 2 for all samples were
performed and m/z peaks with r,0.4 were excluded. Thus, we
obtained four final Mx-Mt lists of m/z peaks: DHB-Fe, DHB-Ga,
CHCA-Fe and CHCA-Ga lists. Selected m/z peaks were
considered consistent peaks.
Discriminant Analysis and model generation
Discriminant Analysis of each final Mx-Mt m/z peak lists was
performed in SPSS 9.0. m/z peaks included in each discriminant
model were included in a second Stepwise Discriminant Analysis,
which allowed the creation of a global discrimination model,
including m/z peaks from all the Mx-Mt combinations.
Supervised hierarchical clustering
Briefly, a vector is assigned to each pseudo-item, and this vector
is used to compute the distances between this pseudo-item and all
remaining items or pseudo-items using the same similarity metric
that was used to calculate the initial similarity matrix. Analyses
were performed in BRB-ArrayTools v3.6.1 developed by Dr.
Richard Simon and Amy Peng Lang.
Decision-tree ensemble algorithm
With the aim of selecting peaks that could differentiate between
histological subtypes of lung cancer samples, we built a multi-peak
classifier using AdaBoost decision tree-based classifier ensemble
[19,20]. Three independent analyses were performed: AC vs.
MALDI Profiling of Lung Cancer
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DHB-Ga m/z peak list. Normalized m/z peak intensity values
from set1 were used as training set. Normalized m/z peak intensity
values from set2 were used as test set. 200 iterations were
performed in all cases. The area under the ROC (Receiving
Operating Characteristic) curve (AUC) equals the probability of
correctly classifying one pair of samples, each one for a separate
class, and is used as a measurement of classifier performance (20).
Statistical analyses were performed in R version 2.4 with the Boost
software package version 1.0-0 and SPSS 9.0.
Statistical analyses for identified peaks
After protein identification by MS/MS, ANOVA (when
possible) and Kruskall-Wallis analyses were performed to assess
differences in the expression of such proteins in the different
histological subtypes. Mann-Whitney’s U was applied to study
differences between two subgroups after Kruskall-Wallis analyses.
Statistical analyses were performed in SPSS 9.0.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks, representative
of NSCLC diagnosis, were retrieved following routine histopath-
ological assessment. Sections were processed using a Dako
Autostainer universal staining system (Dako, Glostrup, Denmark).
For this study, 3.5-mm sections were immunostained with
monoclonal antibody CK8 (1:100 dilution; Novacastra, Newcastle
upon Tyne, UK). Two tissue slices from each sample were
evaluated.
Results
The primary aim of the present study was to test whether tryptic
peptide profiles, obtained from human normal and tumor lung
samples using PIMAC and MALDI-TOF MS techniques, could
discriminate Normal Lung (NL) from lung cancer, as well as
between the most common lung cancer histological subtypes:
AdenoCarcinoma (AC), Large Cell carcinoma (LC) and Squa-
mous Cell carcinoma (SC). Only 49 from 59 samples were selected
for the following analysis because samples without a minimum
content of 50% tumor cells were discarded. Thus, 15 NL, 14 AC,
9 LC and 11 SC samples were subsequently analyzed. The mass
spectrum generated for each sample typically contained several
hundreds of peaks with S/N.3 [5].
Mass signal intensities of tryptic peptides derived from complex
protein mixtures are mediated by several factors, namely relative
protein concentration, varying enzymatic digestion efficiency, and
sequence-dependent desorption/ ionization efficiencies. We per-
formed a highly reproducible spectra processing procedure to
obtain peak profiles with a high degree of concordance in the
sample series. Consistent m/z peaks were selected following these
criteria: mass peaks had to be present in both sample spots and
Pearson’s correlation between intensities of each peak achieved in
Set 1 and Set 2 for all samples had to be .0.4. Mean Pearson’s
correlation coefficient was 0.8 for DHB peaks and 0.65 for CHCA
peaks. An additional requirement (Kruskal-Wallis p-value,0.1)
was applied in order to include peaks with discriminatory power
between the sample subtypes. These criteria provided a consistent
and reproducible methodology, as shown by mean Pearson’s
correlation coefficient of selected mass peaks.
We have investigated the overlap between peaks selected by
each of the Mx-Mt combinations (Figure S1). Overall, 97
consistent mass peaks were identified across the four Mx-Mt
combinations. Regarding MALDI matrices, 81 peaks were
measured in DHB and 41 in CHCA analyses. Contrastingly, 80
peaks were measured in Ga-based IMAC and 42 in Fe-based
IMAC analyses. In both cases, 25 overlapping peaks were found.
Only four peaks were consistently present across all the Mx-Mt
combinations.
Once the consistent peaks had been selected, a Stepwise
Discriminant Analysis was performed in each final Mx-Mt peak
list. Therefore, four discriminant models were constructed and the
mass signals involved in each model are listed in Table S1. All
these discriminant models were able to classify the samples into
four groups, corresponding to NL, AC, SC and LC. Percentages of
correctly classified samples by each model and leave-one-out cross-
validation percentages of correctly classified samples are displayed
in Table S1. A second Stepwise Discriminant Analysis was
performed with peaks included in the four Mx-Mt Discriminant
models (22 peaks) to avoid including noisy mass signals in the
analysis. The Global Model included 9 m/z peaks and correctly
classified 98.0% of the samples (48 of 49) in the LOOCV.
We performed a Supervised Hierarchical Centroid Linkage
Clustering using the 9 peaks included in the Global Model. As
shown in Figure 1, there are two main clusters, separating normal
lung samples from most tumor samples. However, there is not
perfect separation between histological subtypes. With the aim of
selecting mass signals that could characterize samples from one
histological subtype when compared with the other subtypes of
NSCLC samples, AdaBoost decision tree-based classifier ensemble
was performed. Three independent analyses were performed: AC
vs. (SC+LC), LC vs. (AC+SC) and SC vs. (AC+LC), using data in
Set 1 as training set and data in Set 2 as test set from the final
DHB-Ga peak list. The area under the curve (AUC) from ROC
was calculated for each comparison in both training and test set.
The relative influence of each peak in model generation was
obtained. The area under the ROC curve and top peaks for each
comparison are shown in Table 1.
MS/MS identification of some m/z peaks selected by
discriminant and AdaBoost analyses was performed by MALDI-
TOF/TOF (Table S2). In order to evaluate differences in
identified peptide signals among histological subtypes, ANOVA
and Kruskal-Wallis analyses were performed. b-globin mass
signals showed a significantly decreased intensity in tumor samples
when compared with normal lung ones, while GAPDH and b-
actin peaks showed increased intensity in tumor samples. CK8
peak intensity decreased in large cell carcinomas when compared
with adenocarcinoma and squamous cell carcinoma samples.
The pattern of expression by immunohistochemistry (IHC) of
some of these markers was analyzed. The Human Protein Atlas
(http://www.proteinatlas.org/) [21] shows expression and locali-
zation of proteins in a large variety of human normal and cancer
tissues, as well as cell lines with the aid of IHC. IHC expression
profiles for b-actin and GAPDH were evaluated on this useful
database. There is an increased expression of b-actin in some lung
cancer samples when compared with normal ones. However,
GAPDH expression in lung cancer is highly variable. Additionally,
we performed IHC analysis of CK8 expression in five AC, LC and
SC samples. Positive cells for CK8 immunostaining were found in
all LC and AC samples. By contrast, only three of five SC samples
showed positive staining. Positively stained samples showed on
average 20–70% stained cells (Figure 2).
Discussion
Global gene-expression profiling has improved our understand-
ing of the histological heterogeneity of non–small cell lung cancer
and has identified potential biomarkers and gene signatures for
classifying patients with significantly different survival outcomes
MALDI Profiling of Lung Cancer
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carcinogenesis, tumor progression, and metastasis will require an
in-depth analysis of not only the genome, but also the proteome
[23]. Analyses at the gene level cannot detect the biologic
subtleties introduced through post-translational modifications of
proteins and thus requires a proteomic approach [5,24].
Reproducibility has been shown to compromise protein
profiling in all stages, from peptide isolation methods to sample
spectra acquisition and processing [5,11,25,26]. In this study, we
have applied phosphopeptide enrichment chromatographic tech-
niques to reduce the complexity of human lung cancer samples
and analyzed isolated peptides by MALDI-TOF MS. We describe
a mass peak selection method which yields a reproducible peptide
profile from MALDI MS experiments using ClinProTools.
Groseclose et al. described one limitation of using CPT is that
peaks which may be significant among a small subset of spectra in
a group, might become insignificant when averaged with the other
spectra in that group [5]. In order to evaluate as many peaks as
possible, we performed a previous step in the peak selection using
CPT. In each Mx-Mt analysis, all spectra from a single sample
subtype were introduced in CPT, obtaining a subtype character-
istic peak list. Once all subtype lists were obtained, a new list was
generated by combination, including all peaks present in these
subtype lists. Afterwards, spectra from all sample subtypes were
included in CPT, and all peaks in this combined list were
measured. We confirmed that some discriminant peaks were
excluded when spectra from all sample subtypes are included
directly in CPT and standard analysis is performed.
It is noteworthy that when using DHB as a MALDI matrix
provided a higher number of mass peaks as compared to CHCA.
Likewise, the Ga-based IMAC approach produces more mass
signals as compared to the Fe-based assay. In addition, the peak
lists derived from DHB spectra showed a higher mean correlation
between data sets. These results suggest that MALDI analyses
using Ga-based IMAC and DHB as MALDI matrix are more
reproducible and provide a higher number of mass signals. The
peaks identified derived from highly expressed proteins and the
remaining discriminating peptides could not be identified by
MALDI MS. Alternative identification strategies should be tested
in order to increase identification of low-intensity signals in
MALDI MS studies.
Discriminant analyses allowed us to separate normal lung and
NSCLC samples and to identify the peptides which best
discriminated between normal and diseased tissues, as shown by
clustering analysis (Figure 1). However, this task is not usually
problematic due to the important differences between normal and
cancer tissues. What proves trickier is finding differences between
distinct histological subtypes. As showed in Figure 1, there are two
Figure 1. Hierarchical clustering analysis. Heat Map of the Supervised Hierarchical Centroid Linkage Clustering of normalized m/z peak areas, in
two dimensions, for the 49 samples and the 9 m/z peaks included in the global discriminant model.
doi:10.1371/journal.pone.0007731.g001
Table 1. Area under the ROC curve and top AdaBoost selected m/z peaks for each comparison.
Comparison AUC training set AUC test set Top Peak list (m/z)
AC vs. (SC+LC) 0.982 0.961 2202.42, 1515.96, 1535.85, 2005.08, 2780.59
LC vs. (AC+SC) 0.991 0.871 1900.24, 2127.38, 2060.31, 2611.60, 1595.85
SC vs. (AC+LC) 1.000 0.893 2465.46, 2611.60, 2202.42, 2946.71, 2273.30
Adenocarcinoma (AC), Squamous cell Carcinoma (SC), Large cell Carcinoma (LC), Normal Lung (NL).
doi:10.1371/journal.pone.0007731.t001
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and large cell carcinomas separately, but squamous cell carcinoma
samples are splitted between these clusters.
It has been described that ensemble classifiers outperform single
decision trees classifier by having greater accuracies and smaller
prediction errors when applied to proteomics datasets [27]. So, we
tested if AdaBoost analyses could classify the different NSCLC
samples correctly. Our results suggest that AdaBoost can dis-
criminate samples of one lung cancer histological subtype from the
other two. The use of technical replicates as test set allowed us to
assess the robustness of the methodology employed.
Our data suggest that both GAPDH and b-actin have a
significantly increased expression in lung cancer samples. Overex-
pression of GAPDH in human lung cancers was described previously
by Tokunaga et al [28] and there are many publications showing
increased expression of GAPDH in breast [29], pancreatic [30] and
cervical [31,32] human cancers. On the other hand, several studies
indicated that b-actin was differentially expressed in human cancer
(reviewed in 28). Both proteins showed increased levels in rat
hepatoma [33]. Moreover, IHC expression profiles for b-actin and
GAPDH, assessed inthe HumanProtein Atlas,werehighlyvariablein
lung cancer samples. These results question the use of these proteins as
housekeeping products in proteomic analyses of cancer samples.
Cytokeratin 8 (CK8) is a type II intermediate filament protein
that is persistently expressed in most epithelial malignancies [34],
including all NSCLC subtypes [35]. Increased levels of CK8 in
sera have been associated with tumor progression and decreased
survival in patients with NSCLC [36]. In contrast with these
reports, we did not observe increased expression of CK8 in tumor
samples by MALDI-MS analyses. However, we found out that
CK8 levels are decreased in large cell carcinoma samples when
compared with normal lung.
To assess the utility of CK8 expression as a biomarker of large
cell carcinomas, we performed IHC analyses of CK8 expression in
15 lung cancer samples (five AC, five LC and five SC). In our
opinion, no conclusion could be made about the relationship
between IHC and peptide expression profiling from our data. This
difference between techniques could be due to phosphopeptide
enrichment prior to sample analysis or could imply that MS
approaches are more sensitive than IHC. The peptide identified
by MALDI MS/MS (DVDEAYMNKVELES) contains a poten-
tial phosphorylation site at Tyr204, related to phosphorylation by
oncogenic kinases [37]. Previous studies assessing the utility of
CK8 as a biomarker in lung cancer did not include any large cell
carcinoma [35,36].
The study has some constraints. Thus, there is limited capacity
to identify minor mass peaks based on MS/MS analysis of
relatively complex peptide mixtures. However, MALDI MS has
some advantages for biomarker discovery: protein expression and
relative quantification data can be generated for multiple patient
Figure 2. CK8 immunostaining. CK8 immunostaining (Magnification640). Arrows point to tumoral cells. (A) Squamous cell carcinoma of the lung
showing negative stained tumor cells. Lung epithelium shows positive staining. (B) Squamous cell carcinoma of the lung positively stained. (C,D)
Large cell carcinoma of the lung showing different degrees of positive staining. (E,F) Adenocarcinoma of the lung showing different degrees of
positive staining.
doi:10.1371/journal.pone.0007731.g002
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comparison of IHC and peptide profiling expression values
relationship should be done carefully, as it seems that prior
affinity enrichment of samples could introduce some bias.
However, our study does emphasize the great potential of
proteomics in the molecular characterization of cancer. Identifi-
cation of differentially expressed proteins by PIMAC and MALDI-
TOF/TOF MS was performed on fractionated tryptic digests
derived from small amounts of tissues obtained from normal lung
and NSCLC samples. Using an optimized sample preparation
method and a careful data acquisition strategy, we overcame the
major challenge of reproducibility of MALDI MS-based peptide
profiling. Regardless of the nature of the peptides identified by
MS/MS, the appropriate combination of peptide expression
values is able to discriminate normal lung from NSCLC samples
and among the different NSCLC histological subtypes. Future
studies are aimed at establishing peptide profiling as a useful tool
in the discovery of novel biomarkers with potential diagnostic or
theragnostic relevance.
Supporting Information
Figure S1 Venn diagrams showing m/z peaks overlapping
between final m/z peak lists from: (A) four different Mx-Mt
combinations, (B) IMAC resins, and (C) MALDI matrices.
Found at: doi:10.1371/journal.pone.0007731.s001 (0.04 MB PPT)
Table S1 Percentages of correctly classified samples, leave-one
out cross-validation percentages of correctly classified samples and
m/z peaks included in each Mx-Mt combination discriminant
model. Peaks in bold are also included in the 9 m/z peaks global
discrimination model.
Found at: doi:10.1371/journal.pone.0007731.s002 (0.03 MB
DOC)
Table S2 Differentially expressed peptide masses from the
CHCA-MALDI spectra identified by MALDI-TOF/TOF and
MASCOT search engine. Individual MASCOT ions scores are
significant (p,0.05).
Found at: doi:10.1371/journal.pone.0007731.s003 (0.03 MB
DOC)
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